References
- Dal Negro R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis 2008; 3(1):1–10.
- Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004; 7(2):153–67.
- Global Initiative for Chronic Obstructive Lung Disease. Available at http://www.goldcopd.org/uploads/users/files/GOLDReport2006_0122.pdf. Accessed on September 27, 2013.
- Welcome to The Clinical Practice Research Datalink. Available at http://www.cprd.com/home/. Accessed on September 27, 2013.
- MRC dyspnoea scale.. National Institute for Health and Care Excellence. http://www.nice.org.uk/usingguidance/commissioningguides/pulmonaryrehabilitationserviceforpatientswithcopd/mrc_dyspnoea_scale.jsp. Accessed on June 20, 2011.
- Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010; 11:1.
- Department of Health, UK. NHS reference costs 2010–2011. Available at: https://wwwgovuk/government/publications/2010- 11-reference-costs-publication. Accessed on October 4, 2012.
- Personal Social Services Research Unit U. Unit Costs of Health and Social Care 2011. Available at: http://wwwpssruacuk/project-pages/unit-costs/2011/indexphp. Accessed on October 4, 2012.
- Society JFCBMAaRP. British National Formulary 65. 2012. Available at: http://bnforg/bnf/indexhtm. Accessed on October 4, 2012.
- Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis 2012; 7:183–199.
- Akazawa M, Halpern R, Riedel AA, Stanford RH, Dalal A, Blanchette CM. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 2008; 102(12):1744–1752.
- Chittleborough CR, Burke MJ, Taylor AW, et al. Medicare-related service use and costs among people with diagnosed and undiagnosed diabetes and respiratory conditions. Austral Health Rev 2009; 33(1):107–116.
- Nielsen R, Johannessen A, Schnelle HM et al. Repeatability of health economic data in COPD. Respir Med 2008; 102(11):1556–1562.
- Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010; 7(3):214–228.
- Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003; 22(6):931–936.
- Mahler DA, Ward J, Waterman LA, Baird JC. Longitudinal changes in patient-reported dyspnea in patients with COPD. COPD 2012; 9(5):522–527.
- Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK. Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Sympt Manage 2009; 38(1):115–123.
- Müllerova H LC, Tabberer M. Prevalence and burden of breathlessness in COPD patients. Manuscript under review.
- McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001; 4(5):370–375.
- Strong M, South G, Carlisle R. The UK Quality and Outcomes Framework pay-for-performance scheme and spirometry: rewarding quality or just quantity? A cross-sectional study in Rotherham, UK. BMC Health Serv Res 2009; 9:108.